

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/57</b>		A1	(11) International Publication Number: <b>WO 99/49887</b> (43) International Publication Date: <b>7 October 1999 (07.10.99)</b>
(21) International Application Number: <b>PCT/IB98/01917</b>			(AU). SHARP, Phillip [AU/AU]; Biotech Australia PTY. Limited, 28 Barcoo Street, P.O. Box 20, Roseville, NSW 2069 (AU).
(22) International Filing Date: <b>13 November 1998 (13.11.98)</b>			(74) Agent: SANTER, Vivien; Griffith Hack, 509 St. Kilda Road, Melbourne, VIC 3004 (AU).
(30) Priority Data: 60/080,315 1 April 1998 (01.04.98) US 60/084,682 7 May 1998 (07.05.98) US			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/080,315 (CIP) Filed on 1 April 1998 (01.04.98) US 60/084,682 (CIP) Filed on 7 May 1998 (07.05.98)			
(71) Applicant ( <i>for all designated States except US</i> ): BIOTECH AUSTRALIA PTY. LIMITED [AU/AU]; 28 Barcoo Street, P.O. Box 20, Roseville, NSW 2069 (AU).			
(72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): BUNN, Clive, L. [AU/AU]; Biotech Australia PTY. Limited, 28 Barcoo Street, P.O. Box 20, Roseville, NSW 2069 (AU). ANDREWS, John [AU/AU]; Biotech Australia PTY. Limited, 28 Barcoo Street, P.O. Box 20, Roseville, NSW 2069			Published <i>With international search report.</i>

(54) Title: USE OF PROTEASE INHIBITORS FOR TREATING SKIN WOUNDS

## (57) Abstract

The healing of chronic wounds, such as leg ulcers, is accelerated via topical administration of a serine protease inhibitor, such as PAI-2. Wound healing also is promoted using combinations of protease inhibitors, such as PAI-2 with other serine protease inhibitors and/or with protease inhibitors such as inhibitors of metalloproteinases, acid proteases, and thiol proteases, respectively.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USE OF PROTEASE INHIBITORS FOR TREATING SKIN WOUNDS

### BACKGROUND OF THE INVENTION

The skin acts as the body's first line of defense against infection. Accordingly, it is important that lesions or wounds in the skin must be rapidly closed to prevent infection. Some types of wounds, however, are resistant to healing under normal physiological conditions. For example, chronic ulcers may be defined as wounds that fail to heal. Such ulcers are a common complication of diseases such as diabetes or other pathologies where chronic venous insufficiency occurs. Methods of healing such ulcers have received significant attention recently. See, for example, U.S. patents No. 5,693,332 (use of keratinocytes), No. 5,646,117 (use of monocyte chemotactic and activating factor, MCAF), No. 5,202,118 (use of IL-1), and No. 5,599,788 (use of H3 protein), the respective disclosures of which are hereby incorporated by reference in their entireties.

It is apparent, therefore, that improved methods for treating chronic wounds, such as chronic ulcers, are greatly to be desired. In particular, new methods are needed for accelerating healing of chronic wounds.

Previous work has shown that protease activity is increased in chronic wounds. See Palolahti *et al.*, *Exp. Derm.*, 2:29 (1993) and Wysocki *et al.*, *J. Invest. Dermatol.* 101:64 (1993). The present inventors have found that inhibition of this protease activity may be used to treat such chronic wounds.

### SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide improved methods for treating wounds.

5 It is a further object of the present invention to provide pharmaceutical compositions for use in methods of wound healing.

In accomplishing these objects, there has been provided, in accordance with one aspect of the present invention, a method of treating wounds, comprising administering to a patient in need thereof an effective amount of a therapeutic agent comprising a serine protease inhibitor, where the serine protease inhibitor is topically administered to a wound. In one embodiment, the therapeutic agent comprises a urokinase inhibitor. In another embodiment, the therapeutic agent is selected from the group consisting of plasminogen activator inhibitor 2 (PAI-2), a variant thereof having plasminogen activating inhibitory properties, a derivative of PAI-2, and a variant of a derivative of PAI-2. In still another embodiment, the serine protease inhibitor is administered in a gel formulation. The gel may be a cellulose gel further comprising a detergent. The detergent may be Tween-80.

In accordance with another aspect of the invention there has been provided a method of treating wounds comprising administering to a patient in need thereof an effective amount of a therapeutic agent comprising PAI-2, a variant, derivative, or variant of a derivative of PAI-2, and at least one other serine protease inhibitor, where the therapeutic agent is topically administered to the wound. In one embodiment, the other serine protease inhibitor is a uPA inhibitor. In another embodiment, the therapeutic agent further comprises a protease inhibitor selected from the group consisting of thiol protease inhibitors, acid protease inhibitors, and metalloproteinase inhibitors. In yet another embodiment, the protease inhibitors are co-administered with PAI-2, or a variant, derivative, or variant of a derivative of PAI-2. In still further embodiments, the PAI-2 or variant, derivative, or variant of a derivative of PAI-2 is administered in a range of 0.1-2000 µg/cm<sup>2</sup> of wound. In another embodiment, the

PAI-2 or variant, derivative, or variant of a derivative of PAI-2 is administered at least once a day for at least five days.

In further embodiments, the derivative of PAI-2  
5 is obtained by biochemical modification of PAI-2, where the modification is selected from the group consisting of chemical linking with polyethylene glycol, phosphate group attachment, sulfate group attachment, peptidase treatment, treatment with a sugar chain-modifying enzyme, and  
10 treatment with a sugar attachment enzyme. In still other embodiments, a variant of PAI-2 is obtained by deletion or addition of amino acid residues from the amino terminal end of PAI-2. The variant may be obtained by deletion or addition of amino acid residues from the carboxy terminal  
15 end of PAI-2.

In accordance with another aspect of the invention there has been provided a pharmaceutical composition comprising PAI-2 or a PAI-2 derivative, variant or variant of a derivative, in a gel containing a detergent. In one embodiment the detergent is Tween-80, and the gel is a cellulose gel.

In accordance with another aspect of the invention there has been provided a pharmaceutical composition comprising PAI-2 and at least one other serine protease inhibitor. The pharmaceutical composition may further comprise a protease inhibitor selected from the group consisting of thiol protease inhibitors, acid protease inhibitors, and metalloproteinase inhibitors. In another embodiment, the composition is in the form of a  
25 cellulose gel that comprises a detergent.  
30

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples,  
35 while indicating particular embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of

the invention will become apparent to those skilled in the art from this detailed description.

**BRIEF DESCRIPTION OF THE FIGURES**

5

Figure 1 shows the stability of PAI-2 in wound fluid over a 3-hour period. Human oxidised PAI-2 was incubated at 200 IU/ml in wound fluid (diluted 1/10). Residual PAI-2 activity was determined by spectrozyme assay at the  
10 indicated times.

Figure 2 shows the area of ulceration ( $\text{cm}^2$ ) for patients receiving either a placebo (diamonds) or PAI-2 (squares) at various time intervals.

- 5      Figure 3 shows specific uPA activity in patients' wound fluid during the first day of PAI-2 administration.

Figure 4 shows the enhanced release of PAI-2 from a cellulose gel in the presence of Tween80.

10

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides methods and compositions that aid the healing of chronic leg ulcers and other wounds, based on the application of a serine protease inhibitor topically, *i.e.*, to the surface of a wound or ulcer. The skilled artisan will recognize that methods of treating ulcers as described herein also are applicable to treating other skin wounds. In a preferred embodiment, a urokinase plasminogen activator (u-PA) inhibitor is provided as a topical agent.

15      The invention also encompasses compositions comprising a protease inhibitor in conjunction with another protease inhibitor for treating leg ulcers, and methods for treating the ulcers. Thus, methodology and compositions are provided for treating ulcers and other wounds, where a protease inhibitor is used in combination with one or more other protease inhibitors to provide improved wound healing.

20      In a preferred embodiment, plasminogen activator inhibitor 2 (PAI-2) is the topical agent. The properties of PAI-2 are described in detail in Kruithof *et al.*, "Biological and Clinical Aspects of Plasminogen Activator Type II," *Blood* 86:4007 (1995), the contents of which are hereby incorporated by reference. Briefly, PAI-2 is a component of the plasminogen activator (PA) system. The PA system has numerous functions, including regulation of extracellular proteolysis in a wide variety of

physiological processes, such as tissue remodeling, cell migration, wound healing, and angiogenesis.

Plasminogen activators (PA) are serine proteases that convert plasminogen into plasmin, a trypsin-like serine protease, that is responsible not only for the degradation of fibrin, but also contributes to the degradation and turnover of the extracellular matrix. Plasmin can be formed locally at sites of inflammation and repaired by limited proteolysis of its inactive precursor, plasminogen, which circulates in plasma and interstitial fluids. Plasminogen is activated by either urokinase-type plasminogen activator (u-PA) or tissue-type plasminogen activator (t-PA). These catalytic reactions generally take place at the plasma membrane (u-PA) or on a fibrin surface (t-PA). These activating enzymes are produced by a wide range of mesenchymal, epithelial and endoepithelial cells in response to a variety of cytokines and growth factors. Activated plasmin can degrade a wide range of substrates including extracellular matrix macromolecules (excluding collagens) and fibrin. The activities of plasmin and its activating proteinases are regulated extracellularly through a number of protease inhibitors including PAI-2 and plasminogen activator inhibitor-1 (PAI-1).

The present inventors have found that the topical administration of a compound selected from the category of serine protease inhibitors, such as PAI-2, results in a significant decrease in the area of leg ulcers compared to controls. The skilled artisan will recognize that the use of PAI-2 or other serine protease inhibitors in this fashion is not limited to treatment of leg ulcers, but extends to wound healing in general and to the healing of chronic skin wounds or lesions in particular. Examples of such wounds include surgical or trauma wounds, abrasions, skin tears, blisters, pressure ulcers, diabetic ulcers, venous ulcers, arterial ulcers, mixed ulcers, and burns.

In one aspect of the present invention, the serine protease inhibitor PAI-2 is used. Variants of PAI-2, which substantially have the amino acid sequence of PAI-2 and which inhibit plasminogen activators, also can be used as the effective ingredient in wound healing preparations according to the present invention. That is, a "variant of PAI-2" is a protein having substantially the amino acid sequence of PAI-2, to the extent that residues of the PAI-2 amino acid sequence are deleted, added or substituted,

naturally or artificially, but the characteristic inhibitory activity of PAI-2 is not lost. Assays for PAI-2 activity, well known in the art, are readily applicable to the screening of putative variants in this regard.

Thus, conservative, semi-conservative, and other amino acid substitutions are contemplated by the present invention, as long as they do not so reduce activity such that the affected polypeptide is therapeutically ineffective in this context. Sequences in the N-terminal and C-terminal regions of naturally occurring and recombinant PAI-2 may vary – causing an increase or decrease in the number of amino acid residues – depending on the production conditions. These variations specifically are within the scope of the present invention. The skilled artisan will recognize that other active variants of PAI-2 also may be used in the invention, provided that they retain the characteristic protease inhibitor properties of PAI-2.

Also suitable as the active ingredient, pursuant to the present invention, are derivatives that can be produced by chemically or biochemically modifying PAI-2 or a PAI-2 variant. Exemplary of such derivatives are compounds obtained (A) by chemically linking polyethylene glycol or an analogue thereof, (B) by attaching phosphate or sulfate groups, (C) by treatment with a peptidase, such as an endopeptidase, and (D) by treatment with a sugar chain-modifying enzyme or a sugar chain-attaching enzyme, such as sialidase. Derivatives prepared in this fashion can be assayed for protease inhibitor activity by methods that are well known in the art. See, for example, Fersht, ENZYME STRUCTURE AND MECHANISM, 2d ed. W.H. Freeman and Co., 1985, and references therein.

The protease inhibitor, such as PAI-2 or the PAI-2 variants and derivatives described herein (herein collectively referred to as “PAI-2”) may be administered topically to patients in any suitable physiologically acceptable vehicle, for example, in phosphate-buffered saline (PBS) solution. Other vehicles are well known in the art and are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition, Mack Publishing Company, Easton, PA (1990).

The protease inhibitor can be applied to the wound daily, or more or less frequently as required. The skilled artisan will recognize that optimization of dosage

regimens for particular applications is well known in the art, for example as described in REMINGTON'S, *supra*. A typical daily dosage of inhibitor will be 20  $\mu\text{g}$  per  $\text{cm}^2$  of the wound or ulcer, although it will be recognized that this amount may be varied, and concentrations of 0.1-2000  $\mu\text{g}/\text{cm}^2$  advantageously may be used. For example, 5 ulcers of long duration (such as one year or longer) may require concentrations of 500  $\mu\text{g}/\text{cm}^2$  applied multiple times per day, such as, for example, 2, 3, or 4 times daily. For ulcers of lesser duration, or those which are responding well to higher doses, the dose may be lowered. For example, the protease inhibitor dose may be lowered sequentially to, for 10 example, 100, 10, 1, or 0.1  $\mu\text{g}/\text{cm}^2$ . In addition, the application of the inhibitor may be made less frequently, such as from 4 to 1 times daily. PAI-2 does not appear to have systemic toxicity and, therefore, even higher doses may be used if necessary. If necessary, the systemic concentration of PAI-2 can be measured using an ELISA test, and the dosage of PAI-2 can be adjusted accordingly. The toxicity and systemic 15 concentration of other suitable inhibitors can be measured by methods known to those of skill in the art.

The concentration of inhibitor in the vehicle used for application to the patient advantageously is about 1 mg/ml, although higher or lower concentrations can be used if necessary. For example, concentrations as low as about 0.1 mg, or as high as the limit of solubility of inhibitor in the vehicle, may be used.

20 The inhibitor may be applied via short or long term application. Vehicles such as PBS are suitable for short term application of the inhibitor. For longer term application, use of a slow release vehicle is preferred. For example, a gel formulation can be used for effective delivery of the inhibitor. Cellulose derivatives previously have been described to be compatible in gel formulations with certain proteins such as EGF, 25 TGF- $\alpha$ , PDGF and FGF. Proteins in these formulations tend to aggregate over time, however, which is deleterious for the present application. This aggregation is manifested as opalescence or turbidity of the gel, and leads to lower activity of the active protein ingredient, and slower release of the protein from the gel, due to the increased size of the aggregates.

The present inventors have overcome this aggregation problem by the addition of a small amount (up to, and including, 0.05%) of detergent to a inhibitor/cellulose polymer gel. This results in a gel that has substantially improved clarity. The advantages of this gel are shown in more detail in Example 3, *infra*. Detergents such as 5 Tween 80 or Genapol PF10 may be used. The skilled artisan also will recognize that other detergents may also successfully be used.

Unexpectedly, the present inventors have found that, in addition to reducing aggregation in the gel, use of Tween 80 at 0.02% results in enhanced release of the 10 inhibitor from an inhibitor/Natrosol-containing gel. These experiments are described below in Example 3.

The effect of various protease inhibitors on activity of proteases in wound fluid has been studied. These data are described in more detail in Example 3, *infra*.

The present inventors have found that only serine protease inhibitors, particularly uPA inhibitors, are capable of high levels of protease inhibition in wound 15 fluid. To achieve these levels of inhibition, the presence of at least one serine protease inhibitor thus is necessary.

It also is apparent that the inhibitors must be stable in the wound fluid to be effective in aiding wound healing. In the context of the present invention, an inhibitor is suitably stable when it retains at least 50% of its activity after exposure to wound 20 fluid for 3 hours. In this regard, therefore, it is particularly desirable to use an inhibitor that inhibits uPA and is stable in wound fluid. It was observed, for example, that addition of PAI-2 to wound fluid caused the inhibition of uPA activity, and also that PAI-2 was relatively stable in wound fluid, as shown in Figure 1.

By contrast, inhibitors of metalloproteases, acid protease or thiol proteases, 25 when used alone, give much lower amounts of inhibition. See, for example, the data in Example 2, *infra*. The present inventors have found, however, that the efficacy of a single inhibitor may be enhanced by the use of another inhibitor. These combinations of inhibitors can achieve very high levels of inhibition, for example, inhibition of up to 97% of protease activity. For example, the present inventors have found that the

efficacy of PAI-2 may be enhanced by the use of other protease inhibitors in conjunction with PAI-2.

In one embodiment, PAI-2 is used in conjunction with at least one other protease inhibitor. For example, PAI-2 may be used in conjunction with another serine protease inhibitor, such as amiloride, or a derivative thereof.

In another embodiment, PAI-2 is used in conjunction with at least one inhibitor of metalloproteinases, acid proteases and/or thiol proteases. For example, PAI-2 may be used in conjunction with one or more of ethylene diamine tetraacetic acid (EDTA), pepstatin, and N-ethyl maleimide (NEM).

In still another embodiment, PAI-2 is used in conjunction with a combination of at least one other protease inhibitor and at least one other inhibitor of metalloproteinases, acid proteases and/or thiol proteases.

Inhibitors of serine and thiol proteases, and of acid proteases and metalloproteases, are well known in the art, and many are commercially available, for example, from Boehringer Mannheim (Indianapolis, IN), Promega (Madison, WI), Calbiochem (La Jolla, CA), and Life Technologies (Rockville, MD). Other inhibitors are described in well-known texts on enzymology, for example, Fersht, ENZYME STRUCTURE AND MECHANISM, 2d ed. W.H. Freeman and Co., 1985, and references therein.

The protease inhibitors may be applied before or after, or simultaneously with, PAI-2 treatment. The inhibitors also may be applied more or less frequently than PAI-2. In particular, inhibitors that are more rapidly degraded may be applied more frequently than more stable inhibitors. Conversely, more stable inhibitors can be applied less frequently. The skilled artisan will recognize that straightforward assays of inhibitor stability may be used to gauge the frequency of administration of the inhibitors.

Advantageously, the protease inhibitors may be applied in the same vehicle as the PAI-2, although this is not essential for efficacy. In particular, the inhibitors may be applied in the same gel vehicle that may be used for PAI-2, as described above. If the inhibitors are not applied in the same vehicle as PAI-2, then they can be applied in

any pharmaceutically acceptable vehicle, as described, for example, in REMINGTON'S, *supra*.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and  
5 are not intended to be limiting of the present invention.

**Example 1: Use of PAI-2 for Treating Chronic Venous Leg Ulceration.**

*Design.* The study was a double blind placebo controlled randomized trial. A stratified randomization was utilized according to ulcer size. Patients with ulcers less than, and greater than, 20 cm<sup>2</sup> were randomized separately. No minimum or maximum times were set for the patients' current ulcer episode. Minimum and maximum ulcer areas were 2 cm<sup>2</sup> and 50 cm<sup>2</sup>, and a patient's resting ankle brachial doppler arterial pressure index for inclusion was equal to or greater than 0.80.

All patients received compression bandaging. The area of the ulcer was determined by tracing, and the test solution, either PAI-2 at 1.0 mg/ml in phosphate buffered saline, pH 7.0, or buffer alone, was applied at 20 $\mu$ l (20  $\mu$ g in the case of PAI-2) per cm<sup>2</sup>. The patient was asked to lie recumbent on the examination couch while the test solution was applied to the surface of the wound, and to remain there for 15 minutes before bandaging was applied.

Test solution was applied in this manner for five consecutive days. This was followed by visits on days 15, 22, and 29. Ulcer area determination was made on days 1, 5, 15, 22, and 29, ulcer volume was measured by structured light assessment on days 1, 5, and 29, and the ulcer was photographed on days 1, 5, and 29. Adverse events were assessed at each visit, as were concomitant medications.

In addition, wound fluid was collected on the first day before addition of test solution, and 2 hr, 4 hr, and 6 hr afterwards. Wound fluid collection was also made on days 2, 3, 4, and 5 (before test solution addition) and day 29. Blood samples were taken on day 1 at 0 (before), 0.5 hr, 1 hr, and 2 hr after the test solution, and also at day 5. A punch biopsy was taken for histochemical examination of the ulcer edge on day 5.

All wound fluid samples were analyzed for uPA activity by the Chromolise assay, and for total protein by the Bradford assay. If sufficient wound fluid was available, the following assays were also performed, in order of priority: (i) PAI-2 antigen level, by ELISA; (ii) a Western blot to detect whether the PAI-2 molecule was intact, complexed, or in fragments; (iii) total protease activity, determined by a chromogenic assay using azo-casein as substrate, and (iv) total protease activity in the presence of EDTA (to block metalloproteases) or aprotinin (to block plasmin). In addition, blood samples were analyzed by PAI-2 ELISA (0, 0.5, 1, 2 hr on day 1) and analyzed for FBC and clinical chemistry on day 1(0) and day 5.

The Chromolise uPA assay (BioPool Diagnostic kits, Dade International) was used to measure total uPA, that is both active two-chain uPA and inactive single chain uPA, as the latter is converted to the former by the addition of plasmin in the assay. The ELISA used for PAI-2 detected both glycosylated and non-glycosylated PAI-2, and both complexed (with uPA or tPA) and uncomplexed PAI-2. Insufficient wound fluid was obtained for total protease assays in the presence of aprotinin or EDTA. The variation in ulcer volume measurements by structured light assessment was very large: - 20.4% on repeated measurements, so those data could not be used to judge small changes in ulcer volume.

*Results:* Twenty patients completed the full trial protocol, and one completed the first half of the schedule. Overall, 12 patients were randomized to the PAI-2 group and 9 to the placebo group. The incomplete patient was in the PAI-2 group, and those data were included in uPA analysis over days 1-5, but were excluded from analysis of all other parameters over the complete protocol. Throughout the course of the study 23 adverse events were observed, three of which were regarded as serious. But none of the adverse events was deemed related to the PAI-2 treatment. Accordingly, PAI-2 appeared to be safe for topical use in chronic leg ulcers.

The two groups of patients were comparable with respect to age, sex, duration of ulcer and ulcer volume, but the placebo group had a greater initial ulcer size. When the ulcer areas in the two groups were compared over the 29-day course of the study

using the repeated measures analysis of variance, a reduction in the ulcer area in the PAI-2 group was observed, while the placebo group showed no change. The data are shown in the table below:

5      **Placebo**

	Patient number	Day 1	Day 5	Day 15	Day 22	Day 29
10	001	7.30	7.50	7.60	6.20	5.70
	007	14.40	11.30	12.20	12.50	13.60
	009	7.40	6.60	7.70	6.80	8.20
	013	7.30	8.30	8.00	10.00	11.30
	015	10.50	8.80	9.60	8.10	5.20
15	016	3.50	2.80	3.00	2.00	2.20
	032	34.80	32.80	39.20	43.40	39.60
	033	44.70	43.50	43.80	44.80	44.80
	034	22.40	17.60	18.90	16.70	24.60
20	Median (IQR)	10.50 (7.30, 28.60)	8.80 (7.05, 25.20)	9.60 (7.65, 29.05)	10.00 (6.50, 30.05)	11.30 (5.45, 32.10)

**PAI-2**

	Patient number	Day 1	Day 5	Day 15	Day 22	Day 29
25	002	4.50	3.80	4.10	4.10	3.70
	003	7.10	5.20	6.00	5.30	5.00
	004	1.80	1.10	1.10	0.90	1.20
	005	2.60	1.10	0.60	0.30	0.30
	006	19.80	20.10	19.50	20.90	21.50
30	008	4.90	5.20	4.80	3.90	3.80
	010	13.30	13.20	12.60	11.50	3.30
	011	6.60	6.40	6.90	7.70	6.80
	012	5.10	5.60	6.40	0.10	0.00
35	014	2.50	1.40	1.10	2.70	3.90
	017	3.20	3.20	2.40	2.70	3.90
	031	38.00	36.50	25.60	26.30	24.50
40	Median IQR	5.00 (2.75, 11.75)	5.20 (1.85, 11.50)	5.40 (1.43, 11.18)	4.10 (0.90, 11.50)	3.80 (1.20, 6.80)

(IQR-interquartile range)

45

Figure 2 shows the median area of ulceration of the two groups of patients.

PAI-2 was measured in most patients in wound fluid samples taken at 0, 2, 4, and 6 hrs at the first visit. The level of PAI-2 increased dramatically at 2 hr in those patients receiving the drug, and had declined almost to baseline by 4 hr. Western blot analysis of these samples showed the presence of significant amounts of intact PAI-2 at 5 2 hr, which indicated that PAI-2 was not being degraded in this time. Consequently, it is believed that most of the PAI-2 not accounted for at 2 hr, and thereafter, probably had been absorbed into the ulcer. No evidence of systemic distribution of the topically applied PAI-2 was found.

The specific activity of uPA (ng/mg of total protein in wound fluid) declined 10 over 6 hrs on the first day of PAI-2 administration, relative to the placebo group (see Figure 3). However, on subsequent days over the course of the study, there was no significant difference in the uPA activity between the two groups, indicating a "rebound" of uPA synthesis after inhibition by PAI-2.

The difference in uPA between the two groups was not apparent when expressed 15 as units/ml of wound fluid, rather than per mg total protein, indicating differences in water content of the wound fluids. This was not a consequence of the addition of PAI-2 protein, which had no significant effect on the total protein levels. On average, 100 µg PAI-2 was added to a 5 cm<sup>2</sup> ulcer, while the protein content of wound fluid is approximately 30 mg/ml. Total protease activity did not appear to be altered by the 20 addition of PAI-2, whether measured as ng/ml of wound fluid or as ng/mg protein, although statistical evaluation of a larger study population would be useful to confirm this fact.

Histological examination was performed on biopsies taken at visit 5 after staining with hematoxylin and eosin. No evidence of damage to the tissue was observed 25 from the topical application of PAI-2, and there were very few differences in the histopathological descriptions between the two groups. A somewhat reduced incidence of fibrinoid necrosis in the vessels in the biopsies from patients treated with PAI-2 was observed. This effect is likely to be beneficial to the ulcer.

**Example 2: Inhibition of Protease Activity in Wound Fluid**

Wound fluid was collected from patients with chronic venous leg ulcers, and incubated *in vitro* in the presence or absence of each inhibitor along with the protease substrate ZGGRAMC. Cleavage of this substrate indicated protease activity, which was detected by fluorescence at 460nm. Lack of fluorescence indicated inhibition of protease activity.

**Inhibition of Protease Activity in Wound Fluid**

10

**Single Inhibitors**

15

	Inhibitor	Mode of Action	Percent Inhibition
	EGRCK	uPA (non competitive)	94
	Amiloride	uPA (competitive)	96
	Pepstatin	Acid Protease	0
	EDTA	Metalloproteases	0
	NEM	Thiol proteases	21
	AEBSF	Serine proteases (e.g. uPA, tPA)	0

20

**Key:**

EGRCK	glutamic acid-glycine-arginine chloromethyl ketone
EDTA	ethylene diamine tetraacetic acid
NEM	N-ethyl maleimide
AEBSF	4-(2-aminoethyl)-benzene sulphonyl fluoride
ZGGRAMC	carbobenzoxy-glycine-glycine-arginine-aminomethyl coumarin .

30

**Multiple Inhibitors**

35

	Inhibitor	Percent Inhibition
	Pepstatin + EDTA	19
	Pepstatin + NEM	71
	Pepstatin + AEBSF	98
	EDTA + NEM	65
	EDTA + AEBSF	97
	NEM + AEBSF	94
	Pepstatin + EDTA + NEM	60
	Pepstatin + EDTA + AEBSF	98

40

Pepstatin + NEM + AFBSF	93
EDTA + NEM + AFBSF	90
Pepstatin + EDTA + NEM + AEBSF	95

5 Conditions were as described above for single inhibitors.

**Example 3: Preparation of PAI-2-Containing Gels and Measurement of PAI-2 Release**

In these experiments, the PAI-2 containing gel was placed in the top chamber of  
10 a two compartment vessel. The bottom chamber contained buffer, and the two chambers  
were separated by a microporous membrane. The appearance of PAI-2 in the lower  
chamber indicated PAI-2 release from the gel, and was monitored by assays for PAI-2  
activity.

The table below reflects the improved properties of the new PAI-2 gel  
15 formulations. The enhanced released of PAI-2 from the gel is depicted in Figure 4.

CLARITY OF PAI-2 GEL FORMULATIONS

		Excipients				
	Polymer	Conc.(%)	Placebo	None	Genapol PFIO	Tween 80
20	Carbopol 971P	0.5	clear	s.o.	clear	clear
		1.0	clear	s.o.	clear	clear
	Carbopol 974P	0.5	clear	opal	s.o.	s.o.
		1.0	clear	cloudy	opal.	s.o.
25	Carbopol 981	0.5	clear	s.o.	clear	clear
		1.0	clear	s.o.	clear	clear
	Blanose 7LF	2.0	clear	cloudy <sup>d</sup>	v.o. <sup>d</sup>	opal. <sup>d</sup>
	Natrosol 25OHGX	1.5	clear	s.o.	clear	clear
	Keltrol RD	3.0	opal.	cloudy	v.o.	cloudy

30 Key:

opal. = opalescent

s.o. = slightly opalescent

v.o. = very opalescent

<sup>d</sup> = possible microbial contamination

*Methods:*

5 Polymers were dissolved to the desired concentration, and then titrated to pH 7.4-7.7. Detergents were added to 0.05% and PAI-2 to 1mg/ml. Sodium azide (0.05%) was used as a preservative.

10 The invention has been disclosed broadly and is illustrated by reference to representative embodiments described above. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof.

WHAT IS CLAIMED IS:

1. A method of treating wounds comprising administering to a patient in need thereof an effective amount of a serine protease inhibitor, wherein said serine protease inhibitor is topically administered to said wound.
2. The method according to claim 1, wherein said serine protease inhibitor is a urokinase inhibitor.
3. The method according to claim 2, wherein said urokinase inhibitor is selected from the group consisting of PAI-2, a variant thereof having plasminogen activating inhibitory properties, a derivative of PAI-2, and a variant of said derivative.
4. The method according to claim 1, wherein said serine protease inhibitor is administered in a gel formulation.
5. The method according to claim 4, wherein said gel is a cellulose gel further comprising a detergent.
6. The method according to claim 5, wherein said detergent is Tween-80.
7. A method of treating wounds comprising administering to a patient in need thereof an effective amount of a therapeutic agent comprising PAI-2 and at least one other serine protease inhibitor, wherein said therapeutic agent is topically administered to said wound.
8. The method according to claim 7, wherein said other serine protease inhibitor is a uPA inhibitor.

9. The method according to claim 7, wherein said therapeutic agent further comprises a protease inhibitor selected from the group consisting of thiol protease inhibitors, acid protease inhibitors, and metalloproteinase inhibitors.

10. The method according to claim 9, wherein said protease inhibitors are co-administered with PAI-2.

11. A pharmaceutical composition comprising PAI-2 in a gel containing a detergent.

12. A pharmaceutical composition according to claim 11, wherein said detergent is Tween-80, and said gel is a cellulose gel.

13. A pharmaceutical composition comprising PAI-2 and at least one other serine protease inhibitor.

14. A pharmaceutical composition according to claim 13 further comprising a protease inhibitor selected from the group consisting of thiol protease inhibitors, acid protease inhibitors, and metalloproteinase inhibitors.

15. A pharmaceutical composition according to claim 13, wherein said composition is in the form of a cellulose gel that comprises a detergent.

16. The method of claim 3, wherein said PAI-2 is administered in a range of 0.1-2000 µg/cm<sup>2</sup> of wound.

17. The method according to claim 16, wherein said PAI-2 is administered at least once a day for at least five days.


18. The method of claim 3, wherein said derivative thereof is obtained by biochemical modification of PAI-2, wherein said modification is selected from the group consisting of chemical linking with polyethylene glycol, phosphate group attachment, sulfate group attachment, peptidase treatment, treatment with a sugar chain-modifying enzyme, and treatment with a sugar attachment enzyme.

19. The method of claim 3, wherein said variant is obtained by deletion or addition of amino acid residues from the amino terminal end of PAI-2.


20. The method of claim 3, wherein said variant is obtained by deletion or addition of amino acid residues from the carboxy terminal end of PAI-2.

1/4


FIG. 1



2/4




3/4



4/4

**FIG. 4**  
PAI-2/NATROSOL IN-VITRO RELEASE  
(n=2, MEAN +/- SD)



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 98/01917

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int Cl <sup>6</sup> : A61K 38/57		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC: A61K and keywords as indicated below		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
AU: IPC as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
DERWENT : Plasminogen Activator Inhibitor 2, PAI-2, (Urokinase Plasminogen Activator or UPA), (serine protease and inhib: and topical)		
CA, MEDLINE : (Plasminogen Activator Inhibitor 2 or PAI-2 or Minactivin) and (topical or gel or carbopol or blanose or natrosol or keltrol or detergent? or tween or Genapol)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AU 38229/93 A (BEHRINGWERKE AKTIENGESELLSCHAFT) 4 November 1993 whole document	1-20
X	WO 91/03556 A (BIOTECHNOLOGY AUSTRALIA PTY LTD) 21 March 1991 whole document	1-6,11-12,16-20
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
Date of the actual completion of the international search 4 March 1999	Date of mailing of the international search report 18 MAR 1999	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929	Authorized officer  <b>R.L. POOLEY</b> Telephone No.: (02) 6283 2242	

**INTERNATIONAL SEARCH REPORT**

international application No. PCT/IB 98/01917
--

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91/09124 A (BIOTECH AUSTRALIA PTY LIMITED) 27 June 1991 whole document	1-6,11-12,16-20
X	WO 94/05322 A (SUMMIT TECHNOLOGY INC) 17 March 1994 whole document	1-10,13-20
X	AU 40905/89 A (BEHRINGWERKE AKTIENGESELLSCHAFT) 8 March 1990 whole document	1-6,11-12,16-20
X	Patent Abstracts of Japan, JP 6-279316 A (SHISEIDO CO LTD) 4 October 1994	13-15
X	WO 92/06706 A (LEZDEY, J et al) 30 April 1992 whole document	1-2,4-6
X	EP 451130 A (BALTIMORE BIOTECH INC) 9 October 1991 whole document	1-2,4-6
X	Experimental Dermatology, Volume 2, No. 1, February 1993 (PALOLAHTI, M et al), "Proteolytic Activity in Leg Ulcer Exudate", pages 29-37	1,2,4-6
A	British Journal of Dermatology, Volume 138, 1998, (BECHTEL et al), "Plasminogen Activator Inhibitor Type 2 is expressed in Keratinocytes during re-epithelialization of epidermal defects", pages 22-28	

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International application No.  
PCT/IB 98/01917

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
AU	38229/93	CA	2095207	CN	1080873	CZ	9300768
		DE	4214215	EP	567816	HU	65755
		JP	6009425	MX	9302519	NO	931561
		PL	298748	SK	415/93	ZA	9303023
WO	91/03556	AU	62831/90	CA	2041638	EP	446315
		NZ	235182	US	5298400		
WO	91/09124	AU	69671/91	EP	458937	US	5444153
WO	94/05322	GB	2271507				
AU	40905/89	DE	3829523	DK	4280/89	EP	356945
		JP	2108633	PT	91584		
JP	6-279316	NONE					
WO	92/06706	AU	89290/91	CA	2091354	EP	512090
		OA	9768	US	5134119	US	5166134
		US	5190917	US	5217951	US	4916117
		US	5008242	US	5114917		
EP	451130	NONE					
END OF ANNEX							

This page blank (uspto)